Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr.Reddy's Laboratories Ltd    DRREDDY   INE089A01023

DR.REDDY'S LABORATORIES LTD (DRREDDY)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/05/2013 | 10:15am CEST

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:
www.drreddys.com

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at [email protected]/ +91-40-66834297
Saunak Savla at [email protected]/ +91-40-49002135
Milan Kalawadia (USA) at [email protected]/ +1 908-203-4931

Media:
S Rajan at [email protected]/ +91-40-49002445

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DR.REDDY'S LABORATORIES LT
04/25DR REDDY LABORATORIES : `s gets EIR from USFDA for UK plant
AQ
04/25DR REDDY LABORATORIES : Gets eir for uk facility
AQ
04/25DR REDDY LABORATORIES : . Reddy's to Release Q4 and Full Year FY18 Results on Ma..
BU
04/25DR REDDY LABORATORIES : Lab receives EIR on its UK API unit
AQ
04/11DR REDDY LABORATORIES : Drl gets eir from usfda for its plant in mexico
AQ
04/11DR REDDY LABORATORIES : `s gets EIR from USFDA for Cuernavaca plant in Mexico
AQ
04/06DR REDDY LABORATORIES : Indivior files patent lawsuits againt dr reddy's, others
AQ
04/05Indivior Sues Companies for Suboxone Copyright Infringement
DJ
04/03DR REDDY LABORATORIES : announces Senior Leadership Changes
AQ
04/03DR REDDY LABORATORIES : NDA FOR MIGRAINE BY Dr REDDY'S, PROMIUS PHARMA
AQ
More news
News from SeekingAlpha
04/02Dr. Reddy's Lab and Promius Pharma files NDA for its migraine candidate 
03/29Dr. Reddy's Lab announces senior leadership changes 
03/26Dr. Reddy's Laboratories launches Palonosetron Hydrochloride Injection in the.. 
03/16Dr. Reddy's Laboratories launches Levocetirizine Dihydrochloride Tablets USP,.. 
02/19Warren Buffett's Berkshire Claims $358 Million Investment In Teva, But That D.. 
Financials ( INR)
Sales 2018 144 B
EBIT 2018 15 088 M
Net income 2018 11 140 M
Debt 2018 30 776 M
Yield 2018 0,87%
P/E ratio 2018 30,96
P/E ratio 2019 18,73
EV / Sales 2018 2,65x
EV / Sales 2019 2,29x
Capitalization 351 B
Chart DR.REDDY'S LABORATORIES LT
Duration : Period :
Dr.Reddy's Laboratories Lt Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Technical analysis trends DR.REDDY'S LABORATORIES LT
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 42
Average target price 2 583  INR
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Gunupati Venkateswara Prasad Co-Chairman, Chief Executive Officer & MD
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Erez Israeli Chief Operating Officer
Kalpana Jaisingh Morparia Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
DR.REDDY'S LABORATORIES LTD-12.34%5 256
JOHNSON & JOHNSON-9.28%340 239
PFIZER1.60%218 908
NOVARTIS-8.06%203 482
ROCHE HOLDING LTD.-11.08%192 055
MERCK AND COMPANY6.79%162 398